These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17909075)

  • 1. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
    Oflazoglu E; Stone IJ; Gordon KA; Grewal IS; van Rooijen N; Law CL; Gerber HP
    Blood; 2007 Dec; 110(13):4370-2. PubMed ID: 17909075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
    Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
    Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.
    Cerveny CG; Law CL; McCormick RS; Lenox JS; Hamblett KJ; Westendorf LE; Yamane AK; Petroziello JM; Francisco JA; Wahl AF
    Leukemia; 2005 Sep; 19(9):1648-55. PubMed ID: 16049514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
    Borchmann P; Treml JF; Hansen H; Gottstein C; Schnell R; Staak O; Zhang HF; Davis T; Keler T; Diehl V; Graziano RF; Engert A
    Blood; 2003 Nov; 102(10):3737-42. PubMed ID: 12881320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
    Zhang M; Yao Z; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Janik J; Brechbiel MW; Waldmann TA
    Blood; 2006 Jul; 108(2):705-10. PubMed ID: 16551968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
    Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
    Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
    Pasqualucci L; Wasik M; Teicher BA; Flenghi L; Bolognesi A; Stirpe F; Polito L; Falini B; Kadin ME
    Blood; 1995 Apr; 85(8):2139-46. PubMed ID: 7718885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo.
    Maeda N; Muta H; Oflazoglu E; Yoshikai Y
    Cancer Sci; 2010 Jan; 101(1):224-30. PubMed ID: 19799612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies.
    Pinter-Brown LC
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1883-7. PubMed ID: 19012503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
    McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
    Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.
    Sundarapandiyan K; Keler T; Behnke D; Engert A; Barth S; Matthey B; Deo YM; Graziano RF
    J Immunol Methods; 2001 Feb; 248(1-2):113-23. PubMed ID: 11223073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
    Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
    Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.
    Oflazoglu E; Stone IJ; Brown L; Gordon KA; van Rooijen N; Jonas M; Law CL; Grewal IS; Gerber HP
    Br J Cancer; 2009 Jan; 100(1):113-7. PubMed ID: 19066610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
    Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
    Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
    Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
    Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
    Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
    Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
    da Costa L; Renner C; Hartmann F; Pfreundschuh M
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.
    Heuck F; Ellermann J; Borchmann P; Rothe A; Hansen H; Engert A; von Strandmann EP
    J Immunother; 2004; 27(5):347-53. PubMed ID: 15314543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts.
    Tian ZG; Longo DL; Funakoshi S; Asai O; Ferris DK; Widmer M; Murphy WJ
    Cancer Res; 1995 Nov; 55(22):5335-41. PubMed ID: 7585597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.